Trinity Delta view: Oxford BioDynamics’ near-term focus is on securing one or more partnerships, collaborations and licensing deals to maximise the revenue potential of its portfolio of innovative and clinically robust tests. In our view, the market opportunities for CiRT, PSE, and the EpiSwitch test portfolio remain intact and sizeable, but successful uptake requires continued significant commercial investment and/or partners. There are encouraging signs of growth in test volumes, notably PSE, and the potential early submission for CiRT guideline inclusion would also be a positive development. However, longer-term, in our view, sustainable test volume growth will require substantial ongoing commercial investment, and thus third-party partners or further funds are needed to deliver on this potential.
